188 related articles for article (PubMed ID: 21906281)
1. Toxicity report of once weekly radiation therapy for low-risk prostate adenocarcinoma: preliminary results of a phase I/II trial.
Menkarios C; Vigneault É; Brochet N; Nguyen DH; Bahary JP; Jolicoeur M; Beauchemin MC; Villeneuve H; Van Nguyen T; Fortin B; Lambert C
Radiat Oncol; 2011 Sep; 6():112. PubMed ID: 21906281
[TBL] [Abstract][Full Text] [Related]
2. Prospective Phase II Trial of Once-weekly Hypofractionated Radiation Therapy for Low-risk Adenocarcinoma of the Prostate: Late Toxicities and Outcomes.
Zimmermann M; Taussky D; Menkarios C; Vigneault É; Beauchemin MC; Bahary JP; Martin AA; Diaz de Bedoya LV; Lambert C
Clin Oncol (R Coll Radiol); 2016 Jun; 28(6):386-92. PubMed ID: 26782838
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional external-beam radiotherapy for localized prostate adenocarcinoma : a report on acute toxicity.
Norkus D; Miller A; Kurtinaitis J; Haverkamp U; Popov S; Prott FJ; Valuckas KP
Strahlenther Onkol; 2009 Nov; 185(11):715-21. PubMed ID: 19899003
[TBL] [Abstract][Full Text] [Related]
4. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881
[TBL] [Abstract][Full Text] [Related]
5. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer.
Kupelian PA; Reddy CA; Carlson TP; Altsman KA; Willoughby TR
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):904-12. PubMed ID: 12095556
[TBL] [Abstract][Full Text] [Related]
6. Hypofractionated radiation therapy (66 Gy in 22 fractions at 3 Gy per fraction) for favorable-risk prostate cancer: long-term outcomes.
Patel N; Faria S; Cury F; David M; Duclos M; Shenouda G; Ruo R; Souhami L
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):534-9. PubMed ID: 23597418
[TBL] [Abstract][Full Text] [Related]
7. Image guided dose escalated prostate radiotherapy: still room to improve.
Martin JM; Bayley A; Bristow R; Chung P; Gospodarowicz M; Menard C; Milosevic M; Rosewall T; Warde PR; Catton CN
Radiat Oncol; 2009 Nov; 4():50. PubMed ID: 19887007
[TBL] [Abstract][Full Text] [Related]
8. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
[TBL] [Abstract][Full Text] [Related]
9. Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer.
Pellizzon AC; Nadalin W; Salvajoli JV; Fogaroli RC; Novaes PE; Maia MA; Ferrigno R
Radiother Oncol; 2003 Feb; 66(2):167-72. PubMed ID: 12648788
[TBL] [Abstract][Full Text] [Related]
10. Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer.
Zelefsky MJ; Kelly WK; Scher HI; Lee H; Smart T; Metz E; Schwartz L; Fuks Z; Leibel SA
J Clin Oncol; 2000 May; 18(9):1936-41. PubMed ID: 10784635
[TBL] [Abstract][Full Text] [Related]
11. Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II.
Michalski JM; Winter K; Purdy JA; Wilder RB; Perez CA; Roach M; Parliament MB; Pollack A; Markoe AM; Harms W; Sandler HM; Cox JD
Int J Radiat Oncol Biol Phys; 2003 May; 56(1):192-8. PubMed ID: 12694838
[TBL] [Abstract][Full Text] [Related]
12. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma.
Zelefsky MJ; Cowen D; Fuks Z; Shike M; Burman C; Jackson A; Venkatramen ES; Leibel SA
Cancer; 1999 Jun; 85(11):2460-8. PubMed ID: 10357419
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.
Zelefsky MJ; Wallner KE; Ling CC; Raben A; Hollister T; Wolfe T; Grann A; Gaudin P; Fuks Z; Leibel SA
J Clin Oncol; 1999 Feb; 17(2):517-22. PubMed ID: 10080594
[TBL] [Abstract][Full Text] [Related]
14. Hypofractionated helical tomotherapy using 2.5-2.6 Gy daily fractions for localized prostate cancer.
Lopez Guerra JL; Isa N; Matute R; Russo M; Puebla F; Kim MM; Sanchez-Reyes A; Beltran C; Jaen J; Bourgier C; Marsiglia H
Clin Transl Oncol; 2013 Apr; 15(4):271-7. PubMed ID: 22855189
[TBL] [Abstract][Full Text] [Related]
15. Reduction in acute morbidity using hypofractionated intensity-modulated radiation therapy assisted with a fluoroscopic real-time tumor-tracking system for prostate cancer: preliminary results of a phase I/II study.
Kitamura K; Shirato H; Shinohara N; Harabayashi T; Onimaru R; Fujita K; Shimizu S; Nonomura K; Koyanagi T; Miyasaka K
Cancer J; 2003; 9(4):268-76. PubMed ID: 12967137
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer.
Adkison JB; McHaffie DR; Bentzen SM; Patel RR; Khuntia D; Petereit DG; Hong TS; Tomé W; Ritter MA
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):184-90. PubMed ID: 21163590
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionated Dose Escalated 3D Conformal Radiotherapy for Prostate Cancer: Outcomes from a Mono-Institutional Phase II Study.
Tramacere F; Arcangeli S; Pignatelli A; Castagna R; Portaluri M
Anticancer Res; 2015 May; 35(5):3049-54. PubMed ID: 25964594
[TBL] [Abstract][Full Text] [Related]
18. Short-course, intensity-modulated radiotherapy for localized prostate cancer.
Kupelian PA; Willoughby TR
Cancer J; 2001; 7(5):421-6. PubMed ID: 11693901
[TBL] [Abstract][Full Text] [Related]
19. Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost: direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy.
Dolezel M; Odrazka K; Vaculikova M; Vanasek J; Sefrova J; Paluska P; Zouhar M; Jansa J; Macingova Z; Jarosova L; Brodak M; Moravek P; Hartmann I
Strahlenther Onkol; 2010 Apr; 186(4):197-202. PubMed ID: 20354663
[TBL] [Abstract][Full Text] [Related]
20. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.
Michalski JM; Winter K; Purdy JA; Perez CA; Ryu JK; Parliament MB; Valicenti RK; Roach M; Sandler HM; Markoe AM; Cox JD
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):735-42. PubMed ID: 14967428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]